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Abstract
Background: Human aging is associated with profound changes in one of the major epigenetic mechanisms, DNA
methylation. Some of these changes occur in a clock-like fashion, i.e., correlating with the calendar age of an individual,
thus providing a new aging biomarker. Some reports have identified factors associated with the acceleration of the
epigenetic age. However, it is also important to analyze the temporal changes in the epigenetic age, i.e., the duration
of the observed acceleration, and the effects of the possible therapeutic and lifestyle modifications.
Methods: To address this issue, we determined the epigenetic age for a cohort of 183 healthy individuals using blood
samples derived from two time points that were 25 years apart (between 15–24 and 40–49 years of age). Additionally,
we also determined the epigenetic ages of 119 individuals in a cohort consisting of 90-year-old participants
(nonagenarians). These were determined by using the Horvath algorithm based on the methylation level of
353 CpG sites. The data are indicated as the deviation of the epigenetic age from the calendar age (calendar
age minus epigenetic age = delta age, ΔAGE). As obesity is often associated with accelerating aging and
degenerative phenotypes, the correlation of the body mass index (BMI) with the ΔAGE was analyzed in the
following three age groups: young adults, middle-aged, and nonagenarian.
Results: The data showed that BMI is associated with decreased ΔAGE, i.e., increased epigenetic age, in
middle-aged individuals. This effect is also seen during the 25-year period from early adulthood to middle age,
in which an increase in the BMI is significantly associated with a decrease in the ΔAGE. We also analyzed the
association between BMI and epigenetic age in young and elderly individuals, but these associations were not
significant.
Conclusion: Taken together, the main finding on this report suggests that association between increased BMI
and accelerated epigenetic aging in the blood cells of middle-aged individuals can be observed, and this effect
is also detectable if the BMI has increased in adulthood. The fact that the association between BMI and
epigenetic age can only be observed in the middle-aged group does not exclude the possibility that this
association could be present throughout the human lifespan; it might just be masked by confounding factors
in young adults and nonagenarian individuals.
Background
Aging is characterized by a progressive decline in physio-
logical and cognitive functions. The chronological age of
an individual is a natural parameter of choice when
predicting the onset of aging-associated diseases and mor-
tality risk. However, due to the innate complexity of aging,
the onsets of conditions can dramatically vary between
individuals, making chronological age a limited predictor
of aging-associated conditions. To address this discrep-
ancy, there have been numerous attempts to establish a
universal biomarker for aging, i.e., an attribute that would
measure the biological age of an individual [28]. When
the establishment of several disease-specific biomarkers
has been successful, determination of the biological age
of an individual has proven to be a more difficult task.
However, despite the unsuccessful attempts, research
on aging biomarker candidates has been informative
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and increased knowledge on changes in various aging-
associated functions (e.g., inflammatory cytokines and
telomere length) [28].
One of the most recent approaches used to assess the
biological age is the utilization of epigenetic mecha-
nisms, namely, DNA methylation. This approach is
based on the observations that aging is associated with
changes in the DNA methylation levels [6, 12, 18].
More specifically, at the genome-wide level, thousands
of methylation-sensitive cytosine bases residing in the
CpG (cytosine-phosphate-guanine) sites along DNA are
either hyper- or hypomethylated when DNA methy-
lomes of younger and older individuals are compared
(reviewed in [31]). Further analysis of the aging-
associated CpG sites has revealed that several of them
possess an intriguing feature wherein the level of DNA
methylation changes in a clock-like fashion, i.e., correl-
ating with the calendar age of an individual [7]. Using
several publicly available Illumina 27 and 450 K methy-
lation array datasets, Horvath established an algorithm
based on the weighted average of the DNA methylation
levels in 353 CpG sites [7]. This algorithm, the epigen-
etic clock, yields an estimate of the individual’s DNA
methylation age that generally correlates well with a
healthy individual’s calendar age and is claimed to be a
successful predictor in most cell types and tissues. The
acceleration of epigenetic age can be evaluated by cal-
culating the deviation of calendar age from epigenetic
age (ΔAGE). A rapidly increasing number of reports
have identified factors and phenotypes that have an
accelerating effect on the ticking rate of the epigenetic
clock, indicating acceleration of biological aging. Exam-
ples of these include infection with HIV [9] or cyto-
megalovirus [14] and reduced mental and physical
fitness in elderly individuals [16]. Additionally, one
report demonstrates that accelerated epigenetic aging is
associated with a shortened lifespan during follow-up
[17]. Base level of ΔAGE has been shown to be fixed
before adulthood after which there is very little vari-
ation [13].
Obesity has several adverse effects on the body, lead-
ing to increased atherosclerosis, tumorigenesis, neurode-
generation, and type 2 diabetes, i.e., conditions that are
classical features of advanced aging (reviewed in [4]). It
has also been demonstrated that obesity is associated
with a shortened lifespan [4]. Interestingly, although the
health risks associated with overweight and obesity are
well established [23], there is some controversy
surrounding the issue of how this applies to older indi-
viduals. According to the obesity paradox, obese elderly
people have better outcomes in conditions such as
hypertension, coronary artery disease, peripheral artery
disease, and congestive cardiac failure than normal-
weight individuals of the same age [2]. Additionally,
significant decreases in the mortality of obese individuals
with heart failure have been reported compared to their
normal-weight counterparts [27].
To characterize the significance of obesity in epigen-
etic aging, we analyzed the association between BMI and
epigenetic age in three age groups: young adults,
middle-aged, and nonagenarian individuals.
Methods
Study populations
The data from two different study populations were
studied to analyze the relationship between the BMI
and epigenetic age in three age groups: young, middle-
aged, and nonagenarian individuals (Table 1). The
young and middle-aged groups consisted of matched
samples (n = 183) with data from two time points that
were 25 years apart, and the nonagenarian group in-
cluded 119 individuals (women n = 87, men n = 32)
from another study. For the sake of clarity, the age
groups are referred to as YFS1986 (the young group),
YFS2011 (the middle-aged group), and the V90+ (the
nonagenarian group) (for a more detailed description
of the sample populations, see Table 1). The YFS1986
and YFS2011 age groups consisted of the individuals
Table 1 Data summary of the cohorts used in this study. Data
includes mean, standard deviation, and range of calendar age in
years, epigenetic age in years, ΔAGE (difference between
chronological age and epigenetic age) in years, and BMI in kg/m2
YFS1986a
(n = 183)
Young adults
YFS2011b
(n = 183)
Middle-aged
Vitality 90+
(n = 119)
Nonagenarians
Calendar age
Mean 19.2 44.2 90
Standard deviation 3.25 3.25 0c
Range 15–24 40–49 90–90c
Epigenetic age
Mean 17.5 43.6 76.3
Standard deviation 4.36 4.48 6.17
Range 4.87–29.71 33.23–61.37 62–101
ΔAGE
Mean 1.74 0.60 13.71
Standard deviation 2.96 3.70 6.17
Range −6–10.35 −12.53–9.31 −11–28
BMI
Mean 21.32 26.13 26.38
Standard deviation 2.74 4.58 4.86
Range 16.75–34.32 18.87–45.18 13.67–38.26
aYoung Finns Study, samples collected in 1986
bYoung Finns Study, samples collected in 2011
cAll individuals in the Vitality 90+ Study were 90 years old
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from the Cardiovascular Risk in Young Finns Study
(YFS), an ongoing follow-up study with data collected
at several time points from childhood to middle age
(for a more detailed description of the YFS cohort, see
[25]). The YFS1986 and YFS2011 samples collected in
1986 and 2011, respectively, included 183 individuals
(women n = 111, men n = 72). The sample size was
determined by the availability of BMI and DNA
methylation data. The Young Finns Study was ap-
proved by the local ethics committees (the University
Hospitals of Helsinki, Turku, Tampere, Kuopio, and
Oulu) and conducted according to the guidelines of
the Declaration of Helsinki. All participants gave their
written informed consent.
The contribution for the nonagenarian age group was
provided by the participants of the V90+ study, an on-
going prospective population-based study consisting of
individuals aged 90 years and older and living in the
city of Tampere, Finland (for the description of the
recruitment and characterization of the participants,
see [5]). All individuals provided written informed con-
sent, and the research protocol followed the guidelines
of the Declaration of Helsinki. The V90+ study samples
were collected in 2010. The mean ages of the individ-
uals in the three age groups were 19.2 (YFS1986), 44.2
(YFS2011), and 90.0 (V90+) years. All individuals
included in this study were selected from the YFS and
Vitality 90+ study populations based on the availability
of the BMI and DNA methylation array data.
Sample collection
In the Vitality 90+ study, blood samples were drawn into
EDTA tubes by properly trained medical during home
visits. All the samples were collected between 8 and
12 a.m. and leukocyte separation was performed directly
with a Ficoll-Paque density gradient (Ficoll-Paque™ Pre-
mium, cat no. 17-5442-03, GE Healthcare Bio-Sciences
AB, Uppsala, Sweden). Following the separation, the per-
ipheral blood mononuclear cell (PBMC) layers were col-
lected, and DNA was extracted using the spin protocol
for the QIAamp DNA Mini kit (Qiagen, CA, USA),
according to the manufacturer’s instructions. The DNA
concentration was assessed using a Qubit dsDSNA HS
assay (Invitrogen, Eugene, OR, USA), and the quality
was checked with a NanoDrop (Thermo Scientific,
USA). Without the availability of separated PBMCs,
whole blood leukocytes (WBL) were used instead of the
YFS samples. The WBL DNA of the YFS cohorts was
obtained from blood samples stored in EDTA using a
Wizard® Genomic DNA Purification Kit (Promega Cor-
poration, Madison, WI, USA) according to the manufac-
turer’s instructions (for more detailed sample collection
details of YFS, see Nuotio et al. [21]). The quality and
concentration of the WBL DNA was assessed using a
NanoDrop. For the YFS1986 samples, the intactness of
the DNA was assessed by performing PCR for the ame-
logenin gene (AMELX and AMELY).
DNA methylation array
Methylation profiling of the samples in Vitality 90+
study and in YFS2011 was performed at the Institute for
Molecular Medicine Finland (FIMM) Technology
Centre, University of Helsinki. DNA (1 μg) was used for
the bisulfite conversion with the EZ-96 DNA Methyla-
tion Kit (Zymo Research, Irvine, CA, USA), according to
the manufacturer’s protocol. Converted DNA (4 μl) was
whole-genome amplified, enzymatically fragmented, and
hybridized to the Infinium HumanMethylation450 Bead-
Chip (Illumina Inc., CA, USA), covering sequences for
the analysis of 485000 CpG sites. Samples were applied
in the BeadChips in random order. Results were ob-
tained using the iScan reader (Illumina Inc., San Diego,
CA, USA). Methylation profiling of the samples in YFS
from 1986 was performed at Helmholtz Zentrum,
München, Germany, using the same methodology. The
quality of the DNA methylation data was carefully
inspected by standard examinations with principal com-
ponent analysis (PCA) and visualizations with boxplots,
density plots, and dotplots. The possible bias of batch ef-
fects was later addressed by normalizing the DNA
methylation data using the BMIQ function that is imple-
mented in the DNAmAge algorithm, as described below.
The overall quality control was supported by technical
replicates and gender prediction based on the X
chromosome methylation (Additional file 1: Fig. S1).
Quantification of the epigenetic age and deviation of the
calendar age
Obtained probe intensities were transformed to β values
with a standard equation in which β is the ratio of the
methylated probe (m) intensities to the overall inten-
sities (m + u + α, where α is the constant offset, 100, and
u is the unmethylated probe intensity). The resulting β
values ranged from 0 (completely unmethylated, 0) to 1
(fully methylated, 100%). Principal component analysis
(PCA) and visualization of the methylation intensity
values were used to assess the quality control. β values
of the selected probes were used as the input for the cal-
culating the epigenetic age (https://dnamage.genetics.u-
cla.edu/home) [7]. Normalization of the batch effects
was performed with the BMIQ function implemented in
the DNAmAge algorithm. The deviation of the esti-
mated epigenetic age from the actual calendar age was
calculated by subtracting the former from the latter,
yielding ΔAGE (calendar age minus epigenetic age =
delta age, ΔAGE).
Nevalainen et al. Clinical Epigenetics  (2017) 9:20 Page 3 of 9
Correlation analysis of the BMI and ΔAGE
The association between the BMI and ΔAGE was inves-
tigated using Spearman’s rank correlation separately in
each age group. Confounding factors in the association
between the BMI and ΔAGE in the middle-aged group
were addressed with a linear regression model (stepwise,
criteria = PIN(0.05) POUT(0.10)). The following available
variables were used in the regression model to predict
the ΔAGE: BMI, alcohol consumption, smoking, and
gender. The prevalence of chronic diseases and medica-
tions was well below 10%; as a result, they were not in-
cluded in the model.
Results
The mean BMI levels of the young adults, middle-aged,
and nonagenarians were 21.32, 26.13, and 26.38 kg/m2,
respectively. The mean epigenetic ages of these subpop-
ulations were 17.5, 43.6, and 76.3 years (Table 1). The
mean deviations of the epigenetic age from the calendar
age, the ΔAGE, were 1.74, 0.60, and 13.71 years, respect-
ively. The association between the BMI and ΔAGE in
young and middle-aged individuals was analyzed with
matched samples at 25-year interval time points (sam-
ples collected in 1986 and 2011), and the mean calendar
ages of the individuals in these consecutive time points
were 19.2 and 44.2 years, respectively. The WBLs were
used as a source of the DNA. The correlation of ΔAGE
with BMI is shown in Fig. 1 (panel A, young adults;
panel B, middle-aged). In the young adult subpopulation,
the samples were collected in 1986, and there was no
significant association between the ΔAGE and BMI (r =
−0.110, p = 0.138), indicating that BMI did not alter the
ticking rate of the epigenetic clock as these individuals
entered into adulthood. The middle-aged subpopulation,
however, had a significant inverse correlation between
BMI and ΔAGE (r = −0.281, p = 0.0001), suggesting that
higher BMI is associated with acceleration of epigenetic
aging in middle-aged individuals. The gender did not
affect this correlation; the result was also significant
when performed according to gender (Additional file 2:
Table S1 and Additional file 3: Fig. S2). Confounding
factors were addressed with a linear regression model,
and BMI was the single best predictor of the ΔAGE
(Additional file 4: Table S2). Within the nonagenarian
subpopulation, there was no significant association be-
tween the ΔAGE and BMI (r = 0.115, p = 0.211, and
Fig. 2).
To understand the long-term effects of BMI, we ana-
lyzed the association between the change in BMI over a
25-year time range, as well as the ΔBMI (BMI in 2011
minus BMI in 1986) and ΔAGE in middle-aged individ-
uals. Figure 3 shows a significant inverse correlation be-
tween the change in the BMI and ΔAGE (r = −0.193, p =
0.009), suggesting that the individual’s current BMI
status is not the only factor affecting the epigenetic age
and that increased epigenetic age is instead an outcome
of weight gain over time. It should be noted, however,
that only a few individuals showed a decrease in BMI be-
tween these years. As a result, this association mainly
represents the effects of increasing BMI over time.
Discussion
Aging is an extremely complex and heterogenic
phenomenon that is associated with a general decrease
in several cellular and organ functions. Due to this het-
erogeneity, the actual calendar age of an individual
seems to tell very little about what is actually going on
inside the tissues and cells in terms of the aging process
itself. This discrepancy has paved the way for the devel-
opment of an aging biomarker that would estimate the
state of one’s aging process better than chronological
age. One of the most recent approaches to identifying
aging biomarkers is the epigenetic clock, which is based
on the quantification of methylation states of the cyto-
sine bases in the DNA. Since the discovery of the con-
cept of an epigenetic clock [7], numerous studies have
attempted to explain the factors involved in determining
of one’s epigenetic age.
Obesity is linked to aging as it is associated with cer-
tain age-related conditions such as diabetes [1] and
shortening of the telomeres [29]. The role of BMI in the
determination of life-span has been studied extensively.
For example, analysis of the follow-up data of 900000 in-
dividuals (mean recruitment age 46 years, and mean age
at death 67 years) indicated that the mortality was lowest
at a BMI of approximately 22.5−25 kg/m2 and higher;
each 5 kg/m2 increase in the BMI was associated with a
30% higher mortality and association could also be seen
below the 22.5−25 kg/m2 range [24]. Additionally, the
length of the time spent in a high BMI state and lifetime
peak BMI can have a positive association with mortality
[19]. Obesity associated epigenetic changes have also
been looked into. Some studies have reported that in-
creased BMI is associated with hypermethylation of sev-
eral CpG sites within the HIF3A gene [26] as well as
hypermethylation of singe CpG site in TRIM3 gene and
hypomethylation of single CpG site in UBASH3A gene
[30]. Additionally, there are reports regarding association
between global methylation levels of Alu–elements and
BMI [20], and association between obesity and DNA
methylation levels in leptin (LEP) and adiponectin (ADI-
POQ) genes [11]. These obesity-related DNA methyla-
tion changes do not seem to overlap those seen in
aging-associated changes [12, 18]. However, instead of
focusing on single CpG site hypo- or hypermethylation
events, we wanted to explore the relationship between
overweight, as represented by BMI and the epigenetic
age, an aging biomarker calculated using the methylation
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Fig. 1 a Association between ΔAGE (difference between chronological age and epigenetic age in years) and BMI in young adults of the Young
Finns Study (mean age of 19.2 years). Association is non-significant (r = −0.110, p = 0.138). b Association between ΔAGE and BMI in middle-aged
individuals of the Young Finns Study (mean age of 44.2 years, follow-up from Fig. 1a). Correlation is significant (r = −0.281, p = 0.0001)
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Fig. 2 Association between ΔAGE and BMI in nonagenarian individuals of the Vitality 90+ Study (Age of 90 years). Correlation is non-significant
(r = 0.115, p = 0.211). However, it is noteworthy that the trend of correlation is opposite to corresponding ones of the young adults and middle-
aged (Fig. 1a, b). This could be an indication of obesity paradox where higher BMI is beneficial for the elderly individuals
Fig. 3 Association between ΔAGE and change in BMI in a 25-year follow-up in middle-aged individuals of the Young Finns Study. Correlation is
significant (r = −0.193, p = 0.009), indicating that increase in BMI has had an accelerating effect on epigenetic aging
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status of multiple CpG sites. In this study, we investi-
gated the association between BMI and epigenetic age in
the blood cells of three different age groups, the young
adults, the middle-aged, and the nonagenarians. We
found that BMI is not associated with epigenetic aging
in young adults, in the age range from 15 to 24, nor in
nonagenarians, the individuals aged 90 years. In the
middle-aged subpopulation, however, the BMI was in-
versely correlated with individual’s ΔAGE. In addition,
also the change in BMI over 25 years was similarly in-
versely correlated with one’s ΔAGE at the later time
point.
We did not observe the association between BMI and
the acceleration of the epigenetic aging in young adults
(Fig. 1a). It has been shown that epigenetic clock of the
children is ticking relatively faster than that of adults be-
cause of the active, ongoing growth period [7]. Thus, or-
ganismal growth accompanied with the high number of
cell divisions leads to logarithmic ratio of epigenetic age
and calendar age. After the growth period is over, ticking
rate of the epigenetic clock slows down to constant and
increases linearly with calendar age [7]. Therefore, the
finding that increased BMI has not accelerated the epi-
genetic aging of the young adults (mean age of
19.2 years) suggests that obesity-induced acceleration of
the epigenetic age takes place over time, and this popu-
lation has not been exposed to it long enough so that
the effect could be observed. It is also possible that the
effect of increased BMI is minor when compared to epi-
genetic aging induced by normal growth, and therefore
cannot be distinguished.
Epigenetic aging of the older study populations have
also been looked into. It has been shown that extremely
old individuals, such as centenarians, possess significantly
lower epigenetic ages than what their calendar age would
suggest [10]. The older individuals in our study were rep-
resented by the nonagenarians and similar trend was ob-
served, their epigenetic age being on average 13.7 years
lower than their calendar age. This is probably due to the
opposite of what happens during the active growth period,
as the regenerative capacity of the body diminishes [22]
and the epigenetic clock does not keep up. Additionally,
the DNA methylomes of nonagenarians have been ex-
posed to environmental factors for decades and global
aging-associated hypo- and hypermethylation of the CpG
sites could potentially distort the accuracy of DNAmAge
algorithm. However, it is also possible that the nonagenar-
ians are selected in a way that those individuals with
higher epigenetic ages have already died, and those with
relatively lower epigenetic ages are overrepresented in our
study population.
We did not observe significant association between in-
dividual’s BMI and epigenetic age in the nonagenarian
study population. Interestingly, however, the correlation
trend of these variables was opposite to that seen in the
younger and middle-aged individuals, meaning that
higher BMI corresponded to higher ΔAGE, and thus
lower epigenetic age. Although not significant, this dis-
crepancy could be a manifestation of obesity paradox
which suggests that overweight could be in fact benefi-
cial in very old individual, as opposed to young people
for whom it is a risk factor for morbidity and mortality
(reviewed in [2]). In nonagenarians, low BMI, waist-to-
hip ratio, and waist circumference have been shown to
predict mortality [15].
The main finding in this report suggests that increased
BMI is associated with accelerated epigenetic aging in
the blood cells of middle-aged individuals (Fig. 1b). The
mechanisms connecting the numerous metabolic
changes induced by obesity to the process of DNA
methylation can only be proposed at present. Addition-
ally, the role of the obesity-induced degenerative disease
processes cannot be excluded. However, as the individ-
uals of the affected subpopulation are not very old (still
<50 years of age), their role is probably minor. Another
key finding of this study is the observation that the BMI
changes in the 25-year range, from early adulthood to
middle age, can accelerate the ticking rate of epigenetic
clock, indicating that the clock itself is adjustable (Fig. 3).
It should be noted that only a few individuals in this
study demonstrated a decrease in the BMI during the
25-year follow-up; therefore, its effect could not be ana-
lyzed. This information would be decisive for under-
standing the basic mechanisms of the BMI/epigenetic
clock correlation. Implications of accelerated epigenetic
aging are beyond the scope of this article, but according
to literature, these epigenetic alterations could be the
manifestations of accumulated DNA damage over time
[3], establishing the link between epigenetic and calendar
age. If this is the case, it seems implausible that epigen-
etic changes could be reversed by lowering the BMI.
However, additional follow-up studies are needed to in-
vestigate the association between long-term weight re-
duction and epigenetic aging. Understanding this
association could offer important information for plan-
ning various weight reduction or caloric restriction
protocols.
Horvath et al. [8] observed that obesity accelerates epi-
genetic aging of the human liver. However, in contrast
to the data presented here, they did not observe this
phenomenon in DNA derived from blood cells. As the
methodology (source of DNA, methylation assay, and
calculation algorithm) is exactly the same, it is likely that
this discrepancy is due to the differences in the study co-
horts. Our study cohort is very homogeneous, consisting
of individuals with the same ethnic and genetic back-
grounds, which may reduce the effect of possible con-
founders. Moreover, the possibility for follow-up analysis
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increases the reliability of the analysis. It is evident that
very large, well-characterized population cohorts are
required to reveal the factors that influence the ticking
rate of the epigenetic clock. The limitations of our study
include the restricted sample size and slightly differing
source of DNA between the YFS (whole blood) and V90
(PBMC) study populations. However, based on our earl-
ier results, these limitations do not seem to have a major
effect [13].
Conclusions
Overall, our results suggest that accelerated epigenetic
aging could be due to the active growth or regeneration
of tissues. This is evident in the children undergoing the
active growth phase, when their epigenetic clock ticks
faster [7]. In elderly individuals, the regeneration cap-
acity of the tissues and stem cells decreases, leading to
slower ticking of the clock. Somewhere, in between these
two age periods, when the baseline epigenetic aging is
linear, adding fat tissue could be regarded as growth.
Hence, the underlying epigenetic control mechanisms
might be the same as in childhood. The fact that the as-
sociation between BMI and epigenetic age can only be
observed in the middle-aged group, does not exclude the
possibility that this association could be present
throughout the human lifespan; it might just be masked
by confounding factors in young adults and nonagenar-
ian individuals.
Regarding future studies, it would be interesting to
investigate whether increased muscle mass is associated
with accelerated epigenetic aging, as it also involves pro-
liferation of the tissues outside of the active growth
phase. Also, further studies are needed to establish the
more precise mechanisms that operate behind the ob-
served association between epigenetic age and BMI.
Additional files
Additional file 1: Figure S1. The quality control of the DNA
methylation of old DNA samples. YFS1986 samples (young adults) were
collected 30 years ago, and the methylation profiling was performed in
different facility than others. To ensure that these samples did not
include technical biases, we compared the mean methylation of X
chromosome in YFS1986 (X axis) and YFS2011 (Y axis) follow-up samples.
These two cohorts cannot be distinguished from the plot, and only
gender stands out, as expected in the case of DNA methylation.
(DOCX 59 kb)
Additional file 2: Table S1. Gender-specific correlations of ΔAGE and
BMI in three age groups: the young adults (BMI1986 and ΔAGE 1986), the
middle-aged (BMI 2011 and ΔAGE 2011), and the nonagenarians (BMI
2010 and ΔAGE 2010). The correlation is significant only in middle-aged
males and females. (XLSX 10 kb)
Additional file 3: Figure S2. Gender-specific correlations of ΔAGE and
BMI in middle-aged individuals. In panel A, scatterplot of ΔAGE and BMI in
middle-aged female individuals (r=−0265, p=0.05). In panel B, scatterplot of
ΔAGE and BMI in middle-aged male individuals (r=−0.270, p=0.022).
(DOCX 51 kb)
Additional file 4: Table S2. The linear regression model explaining the
variation in ΔAGE of middle-aged adults. We used BMI, gender, smoking,
and alcohol consumption as predictors. Of these, the BMI was the best
independent predictor of ΔAGE (p=0.002). The regression method was
stepwise, criteria=PIN(0.05) POUT(0.10). (DOCX 14 kb)
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